Search

You searched for "palsy"

4041 results found

25-gauge PPV for retained lens fragments

1 February 2016 | | Ophthalmology
This was a retrospective study including 40 eyes of 40 patients with mean age of 78 years, 19 females and 21 males, who underwent 25-gauge pars plana vitrectomy (PPV) for retained lens fragments with a minimum of six months of...

Comparison of retinal pigment epithelium-choroid graft surgery and anti-VEGF therapy in patients with wet AMD

1 December 2015 | | Retina / Uvea / Vitreous
This was a randomised intervention study in wet AMD patients to investigate benefits of free RPE-choroid graft transplantation surgery versus (continuation of) anti-VEGF treatment. Twenty patients who met the inclusion criteria were subdivided into three subgroups, i.e. RPE tears involving...

Stereotactic radiotherapy for polypoidal choroidal vasculopathy

1 August 2015 | | Retina / Uvea / Vitreous
Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular AMD. It is a disease of choroidal vasculature characterised by abnormal branching vascular network with aneurysmal dilatations (polyps). Features of PCV include pigment epithelial detachments (PED), subretinal fluid (SRF) accumulation and...

Does paediatric uveitis reactivate after treatment with anti-TNF-a drugs?

1 June 2015 | | Retina / Uvea / Vitreous
As a potentially blinding disease that can affect 7-27/100000 children, uveitis remains a rare condition, where little evidence based data is available to guide management decisions. Most paediatric uveitis cases are chronic, anterior and non-infectious and may be associated with...

RaScaL Study

1 June 2015 | | Retina / Uvea / Vitreous | Diabetic macular edema, Fluorescein angiography, Anti-VEGF, Ranibizumab, Laser photocoagulation, Combination therapy, Optical coherence tomography
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...

Efficacy of intravitreal dexamethasone implant in patients with persistent macular oedema

1 December 2014 | | Retina / Uvea / Vitreous
Chronic cystoid macular oedema (CME) can develop secondary to various pathologies such as diabetic maculopathy, retinal vein occlusion and uveitis. It can cause significant visual impairment and macular damage. The therapeutic effect of corticosteroids in CME is through one or...

Patients with low vision benefit from optical sector seeing ‘beyond the eyes’

26 February 2019
Patients with low vision are benefitting from an initiative developed by Visualise Training and Consultancy and funded by Thomas Pocklington Trust. Seeing Beyond the Eyes has released its impact report which highlights a huge increase in the number of optical professionals who will now refer patients with low vision to vital support services – up from only 9% to an impressive 96%.

Ophthalmic history made easy

13 March 2019
There are now three ophthalmic medical documentaries to dip into on to Royal College of Ophthalmologists website.

Deadline approaching for Edinburgh scholarship applications

19 June 2019
The University of Edinburgh has opened applications for scholarships to its two online courses, the MSc in Primary Care Ophthalmology and the ChM in Clinical Ophthalmology.

Viral conjunctivitis and COVID-19

23 March 2020 | COVID-19
A joint statement was released by the Royal College of Ophthalmologists and College of Optometrists on 19 March.

Optical practices in England need "financial lifeline"

30 March 2020 | COVID-19
NHS England’s failure to act is forcing hundreds of optical practices to close, with a direct and dangerous impact on the eye healthcare of patients in England during the COVID-19 crisis, the Optical Fees Negotiating Committee (OFNC) has warned.

Johnson & Johnson announces lead vaccine candidate for COVID-19

30 March 2020 | COVID-19
Johnson & Johnson has announced the selection of a lead COVID-19 vaccine candidate and the rapid scaling of its manufacturing capacity with the goal of providing global supply of more than one billion doses.